Evidence map›Paper›PMID 26202247›Full record

ArticleJournal of virology2015

Modulation of Glycosaminoglycans Affects PrPSc Metabolism but Does Not Block PrPSc Uptake.

Hanna Wolf, Andrea Graßmann, Romina Bester, André Hossinger, Christoph Möhl, Lydia Paulsen, Martin H Groschup, Hermann Schätzl, Ina Vorberg

Open access · bronzeAbstract read
In one paragraph

Article in Journal of virology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
0.9field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 16 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 2 countries.

Hanna WolfDeutsches Zentrum für Neurodegenerative Erkrankungen e.V., Bonn, Germany.
Andrea GraßmannDeutsches Zentrum für Neurodegenerative Erkrankungen e.V., Bonn, Germany.
Romina BesterInstitut für Virologie, Technische Universität München, Munich, Germany.
André HossingerDeutsches Zentrum für Neurodegenerative Erkrankungen e.V., Bonn, Germany.
Christoph MöhlDeutsches Zentrum für Neurodegenerative Erkrankungen e.V., Bonn, Germany.
Lydia PaulsenDeutsches Zentrum für Neurodegenerative Erkrankungen e.V., Bonn, Germany.
Martin H GroschupFriedrich-Löffler-Institut, Institute for Novel and Emerging Infectious Diseases, Greifswald-Isle of Riems, Germany.
Hermann SchätzlFaculty of Veterinary Medicine, Department of Comparative Biology and Experimental Medicine, University of Calgary, Calgary, Canada.
Ina VorbergDeutsches Zentrum für Neurodegenerative Erkrankungen e.V., Bonn, Germany Department of Neurology, Rheinische Friedrich-Wilhelms-Universität, Bonn, Germany ina.vorberg@dzne.de.
German Center for Neurodegenerative Diseases · DEFriedrich-Loeffler-Institut · DETechnical University of Munich · DEUniversity of Calgary · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

unlabelledMammalian prions are unconventional infectious agents composed primarily of the misfolded aggregated host prion protein PrP, termed PrP(Sc). Prions propagate by the recruitment and conformational conversion of cellular prion protein into abnormal prion aggregates on the cell surface or along the endocytic pathway. Cellular glycosaminoglycans have been implicated as the first attachment sites for prions and cofactors for cellular prion replication. Glycosaminoglycan mimetics and obstruction of glycosaminoglycan sulfation affect prion replication, but the inhibitory effects on different strains and different stages of the cell infection have not been thoroughly addressed. We examined the effects of a glycosaminoglycan mimetic and undersulfation on cellular prion protein metabolism, prion uptake, and the establishment of productive infections in L929 cells by two mouse-adapted prion strains. Surprisingly, both treatments reduced endogenous sulfated glycosaminoglycans but had divergent effects on cellular PrP levels. Chemical or genetic manipulation of glycosaminoglycans did not prevent PrP(Sc) uptake, arguing against their roles as essential prion attachment sites. However, both treatments effectively antagonized de novo prion infection independently of the prion strain and reduced PrP(Sc) formation in chronically infected cells. Our results demonstrate that sulfated glycosaminoglycans are dispensable for prion internalization but play a pivotal role in persistently maintained PrP(Sc) formation independent of the prion strain. IMPORTANCE: Recently, glycosaminoglycans (GAGs) became the focus of neurodegenerative disease research as general attachment sites for cell invasion by pathogenic protein aggregates. GAGs influence amyloid formation in vitro. GAGs are also found in intra- and extracellular amyloid deposits. In light of the essential role GAGs play in proteinopathies, understanding the effects of GAGs on protein aggregation and aggregate dissemination is crucial for therapeutic intervention. Here, we show that GAGs are dispensable for prion uptake but play essential roles in downstream infection processes. GAG mimetics also affect cellular GAG levels and localization and thus might affect prion propagation by depleting intracellular cofactor pools.

Indexed as

AnimalsBiological TransportBlotting, WesternCell LineChloratesCHO CellsCricetinaeCricetulusDextran SulfateFlow CytometryGlycosaminoglycansImage Processing, Computer-AssistedMiceMice, Inbred C57BLMicroscopy, ConfocalPrion DiseasesChloratesDextran SulfateGlycosaminoglycansPrPSc Proteinssodium chlorate

Identifiers

PMID26202247
PMCPMC4577896
OpenAlexW2150697167

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.